Your shopping cart is currently empty

(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $30 | In Stock | In Stock | |
| 10 mg | $47 | - | In Stock | |
| 25 mg | Preferential | - | In Stock | |
| 50 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | - | In Stock |
| Description | (Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening. |
| Targets&IC50 | FLK1/KDR:2.1 μM, FGFR1:1.2 μM, PDGFRβ:0.008 μM |
| In vitro | (Z)-Orantinib (5-15 minutes) inhibits Flk-1 transphosphorylation, FGFR1 transphosphorylation, and PDGFR autophosphorylation, with Ki values of 2.1 μM, 1.2 μM, and 0.008 μM, respectively [1]. (Z)-Orantinib (0.03-10 μM, 60 minutes) suppresses the increase in KDR tyrosine phosphorylation levels induced by VEGF in HUVECs [1]. (Z)-Orantinib shows dose-dependent inhibitory effects on the mitogenic activity of VEGF- and FGF-induced HUVECs, with IC50 values of 0.34 μM and 9.6 μM, respectively [1]. |
| In vivo | (Z)-Orantinib (4-200 mg/kg, orally administered for 21 days) demonstrated dose-dependent inhibitory effects on the growth of A431 tumors in nude mice [1]. (Z)-Orantinib (75 mg/kg, administered intraperitoneally for 22 days) demonstrated significant inhibition of tumor angiogenesis and vascular formation in mice [1]. (Z)-Orantinib (200 mg/kg, orally administered for 11-27 days) significantly induced regression of established large A431 parazacco spilurus subsp. spilurus xenograft tumors in nude mice [1]. |
| Synonyms | (Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668 |
| Molecular Weight | 310.35 |
| Formula | C18H18N2O3 |
| Cas No. | 210644-62-5 |
| Smiles | C(=C\1/C=2C(NC1=O)=CC=CC2)\C3=C(C)C(CCC(O)=O)=C(C)N3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (128.89 mM), Sonication is recommeded. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.